GILD
Gilead Sciences, Inc.
Stock
$149.05−2.23 (−1.47%)Close Sep 30, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.6B | $10.0B | $10.8B | $8.0B | $9.1B | $11.4B | $8.2B | $9.1B | $8.4B | $11.9B | $17.0B | $21.3B | $12.8B | $3.1B | $3.2B | $3.6B | $2.8B | $3.1B | $2.1B | $1.7B |
| Capital expenditures | $609M | $563M | $523M | $585M | $728M | $579M | $650M | $825M | $924M | — | — | — | — | $134M | — | — | — | — | — | — |
| Free cash flow | $12.9B | $9.5B | $10.3B | $7.4B | $8.3B | $10.8B | $7.5B | $8.3B | $7.5B | — | — | — | — | $3.0B | — | — | — | — | — | — |
| Stock-based compensation | $909M | $894M | $835M | $766M | $637M | $635M | $643M | $636M | $845M | $638M | $380M | $382M | $360M | $252M | $209M | $192M | $200M | $181M | $153M | $185M |
| Buybacks | $1.4B | $1.9B | $1.2B | $1.0B | $1.4B | $546M | $1.6B | $1.7B | $2.9B | $954M | $11.0B | $10.0B | $5.3B | $582M | $667M | $2.4B | $4.0B | $998M | $2.0B | $488M |
| Dividends paid | $4.1B | $4.0B | $3.9B | $3.8B | $3.7B | $3.6B | $3.4B | $3.2B | $3.0B | $2.7B | $2.5B | $1.9B | $0 | $0 | — | — | — | — | — | — |
| Dividends per share | $3.22 | $3.16 | $3.08 | $3.00 | $2.92 | $2.84 | $2.72 | $2.52 | $2.28 | $2.08 | $1.84 | $1.29 | $0.00 | $0.00 | — | — | — | — | — | — |
| Free cash flow margin | 42.5% | 32.1% | 35.8% | 27.4% | 30.6% | 39.6% | 30.5% | 37.1% | 33.8% | — | — | — | — | 26.5% | — | — | — | — | — | — |